Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Triple Negative Breast Cancer
Interventions: DRUG: Combination of Veliparib + Lapatinib
Sponsor: University of Alabama at Birmingham
Collaborators: Breast Cancer Research Foundation of Alabama|GlaxoSmithKline|AbbVie